1SXP — SCHOTT Pharma AG & Co KgaA Income Statement

0.000.00%

Last trade - 00:00

HealthcareAdventurousMid CapFalling Star

Annual income statement for SCHOTT Pharma AG & Co KgaA, fiscal year end - September 30th, EUR millions except per share, conversion factor applied.

	2021 September 30th	2022 September 30th	2023 September 30th	2024 September 30th	2025 September 30th
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	ARS	ARS	ARS	ARS	ARS
Standards:	—	—	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	649	821	899	957	986
Cost of Revenue
Gross Profit	226	296	316	323	332
Selling / General / Administrative Expenses
Research And Development
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses	521	657	706	765	785
Operating Profit	128	164	192	193	201
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	123	158	186	184	188
Provision for Income Taxes
Net Income After Taxes	101	126	152	150	147
Minority Interest
Net Income Before Extraordinary Items
Net Income	101	125	152	150	146
Adjustments to Net Income
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	101	125	152	150	146
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	0.667	0.886	0.971	0.991	0.971
Dividends per Share